-
Something wrong with this record ?
Evaluation of ECG time intervals in a rabbit model of anthracycline-induced cardiomyopathy, a useful tool for assessment of cardioprotective agents
Anna Potáčová, Michaela Adamcová, H. Čajnáková, L. Hrbatová, Martin Štěrba, Olga Popelová, Tomáš Šimůnek, Přemysl Poňka, Vladimír Geršl
Language English Country Czech Republic
NLK
Directory of Open Access Journals
from 1991
Free Medical Journals
from 1998
ProQuest Central
from 2005-01-01
Medline Complete (EBSCOhost)
from 2006-01-01
Nursing & Allied Health Database (ProQuest)
from 2005-01-01
Health & Medicine (ProQuest)
from 2005-01-01
ROAD: Directory of Open Access Scholarly Resources
from 1998
- MeSH
- Anthracyclines adverse effects therapeutic use toxicity MeSH
- Iron Chelating Agents therapeutic use MeSH
- Daunorubicin adverse effects therapeutic use toxicity MeSH
- Electrocardiography utilization MeSH
- Research Support as Topic MeSH
- Cardiomyopathies drug therapy complications prevention & control MeSH
- Rabbits MeSH
- Razoxane adverse effects therapeutic use toxicity MeSH
- Troponin MeSH
- Animals MeSH
- Check Tag
- Rabbits MeSH
- Animals MeSH
The aim of this study was to analyze the ECG time intervals in the course of the development of chronic anthracycline cardiomyopathy in rabbits. Furthermore, this approach was employed to study the effects of a model cardioprotective drug (dexrazoxane) and two novel iron chelating compounds - salicylaldehyde isonicotinoyl hydrazone (SIH) and pyridoxal 2-chlorobenzoyl hydrazone (o-108). Repeated daunorubicin administration induced a significant and progressive prolongation of the QRS complex commencing with the 8th week of administration. At the end of the study, we identified a significant correlation between QRS duration and the contractility index dP/dtmax (r = -0.81; P<0.001) as well as with the plasma concentrations of cardiac troponin T (r = 0.78; P<0.001). In contrast, no alterations in ECG time intervals were revealed in the groups co-treated with either dexrazoxane or both novel cardioprotective drugs (SIH, o- 108). Hence, in this study, the QRS duration is for the first time shown as a parameter suitable for the non-invasive evaluation of the anthracycline cardiotoxicity and cardioprotective effects of both well established and investigated drugs. Moreover, our results strongly suggest that novel iron chelators (SIH and o-108) merit further study as promising cardioprotective drugs against anthracycline cardiotoxicity.
Grant č. 0021620820 MSM
Bibliography, etc.Lit.: 14
- 000
- 03764naa 2200517 a 4500
- 001
- bmc07502303
- 003
- CZ-PrNML
- 005
- 20111210121410.0
- 008
- 080305s2007 xr e eng||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Potáčová, Anna. $7 xx0193799
- 245 10
- $a Evaluation of ECG time intervals in a rabbit model of anthracycline-induced cardiomyopathy, a useful tool for assessment of cardioprotective agents / $c Anna Potáčová, Michaela Adamcová, H. Čajnáková, L. Hrbatová, Martin Štěrba, Olga Popelová, Tomáš Šimůnek, Přemysl Poňka, Vladimír Geršl
- 314 __
- $a Faculty of Medicine, Charles University, Hradec Králové
- 500 __
- $a Grant č. 0021620820 MSM
- 504 __
- $a Lit.: 14
- 520 9_
- $a The aim of this study was to analyze the ECG time intervals in the course of the development of chronic anthracycline cardiomyopathy in rabbits. Furthermore, this approach was employed to study the effects of a model cardioprotective drug (dexrazoxane) and two novel iron chelating compounds - salicylaldehyde isonicotinoyl hydrazone (SIH) and pyridoxal 2-chlorobenzoyl hydrazone (o-108). Repeated daunorubicin administration induced a significant and progressive prolongation of the QRS complex commencing with the 8th week of administration. At the end of the study, we identified a significant correlation between QRS duration and the contractility index dP/dtmax (r = -0.81; P<0.001) as well as with the plasma concentrations of cardiac troponin T (r = 0.78; P<0.001). In contrast, no alterations in ECG time intervals were revealed in the groups co-treated with either dexrazoxane or both novel cardioprotective drugs (SIH, o- 108). Hence, in this study, the QRS duration is for the first time shown as a parameter suitable for the non-invasive evaluation of the anthracycline cardiotoxicity and cardioprotective effects of both well established and investigated drugs. Moreover, our results strongly suggest that novel iron chelators (SIH and o-108) merit further study as promising cardioprotective drugs against anthracycline cardiotoxicity.
- 650 _2
- $a antracykliny $x škodlivé účinky $x terapeutické užití $x toxicita $7 D018943
- 650 _2
- $a daunomycin $x škodlivé účinky $x terapeutické užití $x toxicita $7 D003630
- 650 _2
- $a razoxan $x škodlivé účinky $x terapeutické užití $x toxicita $7 D011929
- 650 _2
- $a chelátory železa $x terapeutické užití $7 D007502
- 650 _2
- $a elektrokardiografie $x využití $7 D004562
- 650 _2
- $a kardiomyopatie $x farmakoterapie $x komplikace $x prevence a kontrola $7 D009202
- 650 _2
- $a troponin $7 D014336
- 650 _2
- $a králíci $7 D011817
- 650 _2
- $a finanční podpora výzkumu jako téma $7 D012109
- 650 _2
- $a zvířata $7 D000818
- 700 1_
- $a Adamcová, Michaela, $d 1964- $7 xx0064762
- 700 1_
- $a Čajnáková, H. $7 _BN002374
- 700 1_
- $a Hrbatová, L. $7 _BN002375
- 700 1_
- $a Štěrba, Martin. $7 xx0076492
- 700 1_
- $a Popelová, Olga. $7 _BN001885
- 700 1_
- $a Šimůnek, Tomáš $7 xx0019029
- 700 1_
- $a Poňka, Přemysl, $d 1941- $7 jk01100569
- 700 1_
- $a Geršl, Vladimír, $d 1946-2015 $7 nlk19990073168
- 773 0_
- $w MED00003824 $t Physiological research $g Roč. 56, č. 2 (2007), s. 251-254 $x 0862-8408
- 856 41
- $u http://www.biomed.cas.cz/physiolres/pdf/56/56_251.pdf $y plný text volně přístupný
- 910 __
- $a ABA008 $b A 4120 $c 266 $y 1
- 990 __
- $a 20080304105411 $b ABA008
- 991 __
- $a 20080305164509 $b ABA008
- 999 __
- $a ok $b bmc $g 617923 $s 470355
- BAS __
- $a 3
- BMC __
- $a 2007 $b 56 $c 2 $d 251-254 $i 0862-8408 $m Physiological research $x MED00003824
- LZP __
- $a 2007-22/mkal